Table 1. Baseline characteristics by study treatment allocation of participants alive at day 90 and those consenting to clinical follow-up in the POST-RENAL study.
| Characteristic | Alive at Day 90 (n = 810) | Consented to Clinical Follow-up (n = 350) | ||
| Lower Intensity | Higher Intensity | Lower Intensity | Higher Intensity | |
| Number of participants | 411 | 399 | 188 | 162 |
| Age in years | 62.5 (16) | 62.9 (15) | 61.3 (16) | 62.2 (14) |
| Male sex n (%) | 260 (63.3) | 257 (64.4) | 133 (70.7) | 112 (69.1) |
| Mean preadmission eGFRa | 58.7 (28) | 52.7 (32) | 59.9 (27) | 56.1 (30) |
| Time in ICU before randomization (h, median ± IQR) | 4 (18–45) | 5 (18–48) | 7 (24–57 | 6 (17–45) |
| Mechanical ventilation – n (%) | 281 (68.4) | 266 (66.7) | 135 (71.8) | 113 (69.8) |
| Severe sepsis – n (%) | 177 (43.1) | 191 (47.9) | 81 (43.1) | 84 (51.9) |
| APACHE III score (mean ± SD) | 97.9 (24) | 97 (23) | 97.8 (23) | 95.4 (23) |
| Weight – kg (mean ± SD) | 81.3 (13) | 81.9 (13) | 81.7 (13) | 83 (13) |
| Non-operative primary diagnosis – n (% of total) | 279 (67.8) | 294 (73.6) | 123 (65.4) | 115 (70.9) |
| Cardiovascular (n, % of non-op) | 138 (49.4) | 142 (48.3) | 65 (52.8) | 62 (53.9) |
| Genitourinary (n, % of non-op) | 75 (26.8) | 82 (27.8) | 26 (21.1) | 29 (25.2) |
| Respiratory (n, % of non-op) | 29 (10.4) | 39 (13.3) | 15 (12.2) | 16 (13.9) |
| Gastrointestinal (n, % of non-op) | 20 (7.2) | 17 (5.8) | 9 (7.3) | 5 (4.3) |
| Other (n, % of non-op) | 17 (6) | 14 (4.8) | 8 (6.5) | 3 (2.7) |
| Operative primary admission diagnoses – n (% of total) | 132 (32.1) | 105 (26.3) | 65 (34.6) | 47 (29) |
| Cardiovascular (n, % of operative) | 87 (65.9) | 70 (66.7) | 43 (66.1) | 30 (63.8) |
| Gastrointestinal (n, % of operative) | 25 (18.9) | 23 (21.9) | 13 (20) | 11 (23.4) |
| Trauma (n, % of operative) | 9 (6.8) | 5 (4.8) | 4 (6.2) | 3 (6.4) |
| Other (n, % of operative) | 11 (8.3) | 7 (6.7) | 5 (7.7) | 3 (6.4) |
| Criteria for use of RRTb | ||||
| Oliguria (n, %) | 256 (62.2) | 229 (57.4) | 112 (59.6) | 96 (59.3) |
| Hyperkalaemia (n, %) | 31 (7.5) | 40 (10) | 11 (5.9) | 15 (9.3) |
| Severe acidosis (n, %) | 141 (34.3) | 123 (30.8) | 60 (31.9) | 44 (27.2) |
| BUN > 25 mmol/l (n, %) | 145 (35.3) | 180 (45.1) | 65 (34.3) | 65 (40.1) |
| Creatinine > 300 µmol/l (n, %) | 222 (54) | 227 (56.9) | 99 (52.7) | 89 (54.9) |
| Severe organ oedema associated with AKI (n, %) | 174 (42.3) | 174 (43.6) | 75 (39.9) | 67 (41.4) |
| BUN (mmol/l, mean ± SD) | 22.2 (12) | 24.4 (13) | 21.5 (11) | 22.6 (13) |
| Creatinine before randomization (µmol/l, mean ± SD) | 136 (115) | 156 (117) | 133 (123) | 143 (88) |
| Bicarbonate (mmol/l, mean ± SD) | 18.3 (5.9) | 18.0 (5.4) | 18.7 (6.3) | 18.5 (5.7) |
a
Pre-admission renal function was only available on 433/810 (53%) of day 90 survivors of the RENAL Study.
b
Percentage adds up to >100 owing to the presence of more than 1 criteria in some patients